Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The UK’s National Institute for Health and Care Excellence (NICE) is now recommending insertion of endobronchial valves used to treat severe emphysema, and the Interventional Procedures Advisory Committee that wrote the recommendations points out that most of the support for this procedure comes from trials of Pulmonx' Zephyr "duckbill" endobronchial valve.
Latest From Market Access
A proposed coverage policy from the US Centers of Medicare and Medicaid Services would not only cover magnetic resonance imaging for patients with an implanted cardiac rhythm management device with an FDA-approved indication for MRI-compatibility, but will also cover MRI in patients with devices without that FDA labeling in certain circumstances.
2017 saw developments that were beneficial to the Turkish medtech industry, like the continued progress of the billion-dollar City Hospitals project, but also initiatives such as forthcoming Online Health System Market that will have a mixed impact on industry players. Additionally, the year also saw medtech suppliers increasingly frustrated by the growing debt that is owed to them by Turkey's hospitals, an issue that remains unresolved. This article give an overview of the Turkish medtech market in 2017 and developments to look out for this year.
In spite of the increased attention medtech companies have been paying over the last few years to the emerging countries, the US remains undeniably the biggest market for medical devices. Yet, this market continues to leave many European medtech firms stumped. In this article, the second in a four-part series focused on sales strategies, Brian Chapman and Lukas Grabner of global sales and marketing strategy consulting firm ZS list the key reasons why European companies are struggling to conquer the US and how they can overcome these hurdles.
2017 was obviously dominated by news of political chaos coming out of the White House and, for the medtech industry, the year was bookended by its failure to win repeal of the medical device tax. But last year was an extremely fruitful period for new US FDA policies, pilot programs and other approaches intended to streamline the scrutiny of devices. Medtech Insight readers couldn't get enough of coverage and insights on US FDA inspections and compliance topics, which dominated our top 25 most popular US regulatory and policies stories for last year. Also making the list were pieces delving into the evolving, and very active, FDA under Scott Gottlieb, the agency's growing attention to digital health, and the impact of the Trump administration's deregulation emphasis.
The Accelerated Access Review, part of the UK's renewed push to speed access to innovations for system efficiency, cost savings and outcomes improvements, strikes most of the right notes, but there is still room for improvement in the framework of innovation adoption by the NHS, according to an industry-commissioned response to the review.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.